# SQ3370 in advanced solid tumours and soft tissue sarcoma (SQ3370-001, phase 1/2a)

Source: https://onco.cc/trials/nct04106492/  
OnCo record `nct04106492` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Described by its investigators as the first use of click chemistry inside patients. A gel was injected into one tumour and an inactive form of doxorubicin was given into a vein, to be switched on at the gel. Doses far above the usual doxorubicin dose were tolerated, but tumours shrank in 2 of 14 sarcoma patients, no more often than with ordinary doxorubicin, and the sponsor stopped the trial.

## Summary

A multicentre, open-label, non-randomised phase 1/2a study sponsored by Shasqi, registered in September 2019 and started on 1 August 2020 at seven centres in the United States and three in Australia. Each 21-day cycle began with 10 or 20 mL of the biopolymer SQL70 injected into a single lesion, followed by the doxorubicin prodrug SQP33 infused daily. The registry lists nine dose-escalation cohorts from 8 to 315 mg/m2 of SQP33 a day for five days with 10 mL of SQL70, two cohorts with 20 mL, one further cohort at 185 mg/m2 a day (Cohort A) and three phase 2a groups, 53 participants in all.

Phase 1 set out to find the recommended phase 2 dose, which the posted results give as 1250 mg/m2 of SQP33 per cycle. The preprint reporting the whole trial describes 39 phase 1 patients treated at 0.38 to 15 times the standard doxorubicin dose with no dose-limiting toxicity, and 12 times chosen as the recommended dose.

Phase 2a tested that dose in soft tissue sarcoma on three-day and five-day schedules. The registry's response table shows objective responses in 2 of 15 participants: none of 1 in a cohort below the recommended dose, 1 of 2 in the extremity sarcoma group, none of 6 on the three-day schedule and 1 of 6 on the five-day schedule. The preprint reports an unconfirmed objective response rate of 14.3 per cent (2 of 14) and disease control in 71.4 per cent (10 of 14; 95% CI 41.9 to 91.6), with tumour shrinkage in injected and non-injected lesions.

The registry records the study as terminated by the sponsor's decision, with primary completion on 7 September 2023. The preprint gives the reason: the prespecified criterion for continuing, a response rate greater than that of standard doxorubicin, was not met. Across all 53 participants the registry reports 2 deaths from any cause and 15 people with at least one serious adverse event over the one-year reporting period.

## Fields

- Kind: Trial
- Status: mixed
- Last checked: 2026-11-16
- Also known as: SQ3370-001; Phase 1/2a Study of SQ3370 in Patients With Advanced Solid Tumors
- Tags: failure
- Registry id: NCT04106492
- Phase: 1/2
- Setting: Adults with locally advanced or metastatic solid tumours that could be injected (phase 1), then anthracycline-naive adults with unresectable or metastatic soft tissue sarcoma (phase 2a)
- Sponsor: Shasqi, Inc.
- Enrolled: 53
- Result: Recommended phase 2 dose 1250 mg/m2 of SQP33 per cycle, with no dose-limiting toxicity up to 15 times the standard doxorubicin dose. In phase 2a, 2 of 14 patients with soft tissue sarcoma had an unconfirmed objective response (14.3 per cent), comparable to standard doxorubicin; the trial was stopped because its prespecified response criterion was not met.
- Outcomes: Recommended phase 2 dose of SQP33 (phase 1): Dose escalation with 10 mL SQL70 1250 mg/m2 per cycle vs Dose escalation with 20 mL SQL70 1250 mg/m2 per cycle; Participants with an objective response (phase 2a, RECIST, by MRI): Cohort A, 185 mg/m2 a day (below the recommended dose) 0 participants vs Phase 2a group 1, extremity soft tissue sarcoma 1 participants vs Phase 2a group 2, three-day schedule 0 participants vs Phase 2a group 2, five-day schedule 1 participants; Unconfirmed objective response rate, soft tissue sarcoma at the recommended dose (preprint): SQ3370 phase 2a 14.3 percent; Disease control rate, soft tissue sarcoma at the recommended dose (preprint): SQ3370 phase 2a 71.4 percent
- Replication: None. This is the only registered trial of SQ3370 and the only human study of this click-activated design; it had no comparison arm.

## Notes

- The registry's stated reason for stopping is "Sponsor's decision"; the response criterion is the reason given in the investigators' preprint.
- The registry and the preprint count the phase 2a response population differently (15 and 14); both report two responses.
- Results were first posted on ClinicalTrials.gov on 14 November 2025. The planned interim analysis was presented at ASCO 2024 (abstract 11555), with the same response rate.

## Sources

- ClinicalTrials.gov NCT04106492: https://clinicaltrials.gov/study/NCT04106492
- ClinicalTrials.gov: posted results: https://clinicaltrials.gov/study/NCT04106492?tab=results
- Chawla et al., medRxiv 2025 (preprint): https://doi.org/10.1101/2025.06.02.25328445
- Srinivasan et al., Clinical Cancer Research 2025: https://doi.org/10.1158/1078-0432.CCR-24-2539
- Bui et al., ASCO 2024 abstract 11555: https://doi.org/10.1200/JCO.2024.42.16_suppl.11555

## Connected records

- cancers: [Sarcomas (soft tissue, bone, GIST)](https://onco.cc/cancers/sarcoma/)
- technologies: [Click-activated prodrugs (bioorthogonal drug activation in the body)](https://onco.cc/technologies/click-activated-prodrugs/)
- drugs: [SQ3370](https://onco.cc/drugs/sq3370/)
- companies: [Shasqi](https://onco.cc/companies/shasqi/)
- institutions: [Chris O'Brien Lifehouse](https://onco.cc/institutions/chris-obrien-lifehouse/), [City of Hope](https://onco.cc/institutions/city-of-hope/), [MD Anderson Cancer Center](https://onco.cc/institutions/md-anderson/), [Sarcoma Oncology Center](https://onco.cc/institutions/sarcoma-oncology-center/)
- terms: [Dose-limiting toxicity (DLT)](https://onco.cc/terms/dose-limiting-toxicity/), [Objective response rate (ORR)](https://onco.cc/terms/orr/), [Recommended phase 2 dose (RP2D)](https://onco.cc/terms/rp2d/)
- people: [Sant P. Chawla](https://onco.cc/people/sant-chawla/)
- key papers: [SQ3370 from preclinical evaluation to a first-in-human dose-escalation trial: the first click chemistry-based cancer therapeutic](https://onco.cc/key-papers/paper-srinivasan-sq3370-preclinical-to-first-in-human-clin-cancer-res-2025/), [SQ3370 phase 1/2a results in advanced solid tumours and soft tissue sarcoma (preprint)](https://onco.cc/key-papers/paper-chawla-sq3370-phase-1-2a-advanced-solid-tumours-medrxiv-2025/)

---
JSON: https://onco.cc/api/v1/entities/nct04106492.json